Merit Medical Systems (NASDAQ:MMSI) Rating Increased to Strong-Buy at Zacks Research

Zacks Research upgraded shares of Merit Medical Systems (NASDAQ:MMSI) from a hold rating to a strong-buy rating in a research note issued to investors on Tuesday,Zacks.com reports. Zacks Research also issued estimates for Merit Medical Systems’ Q4 2026 earnings at $0.98 EPS, FY2026 earnings at $3.73 EPS, Q1 2027 earnings at $0.88 EPS, Q2 2027 earnings at $1.02 EPS, Q3 2027 earnings at $1.01 EPS, Q4 2027 earnings at $1.10 EPS, FY2027 earnings at $4.01 EPS, Q1 2028 earnings at $0.95 EPS, Q2 2028 earnings at $1.11 EPS and FY2028 earnings at $4.32 EPS.

A number of other equities research analysts have also issued reports on MMSI. Barrington Research set a $114.00 target price on shares of Merit Medical Systems in a research note on Friday, July 31st. Raymond James Financial reiterated an “outperform” rating and issued a $100.00 price target on shares of Merit Medical Systems in a research note on Friday, July 31st. JPMorgan Chase & Co. upped their price target on Merit Medical Systems from $77.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. BTIG Research reiterated a “buy” rating and set a $105.00 target price on shares of Merit Medical Systems in a research note on Tuesday, August 11th. Finally, Wells Fargo & Company increased their target price on shares of Merit Medical Systems from $74.00 to $83.00 and gave the stock an “equal weight” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $100.00.

Merit Medical Systems Stock Down 0.6%

MMSI stock opened at $90.54 on Tuesday. The company has a current ratio of 4.20, a quick ratio of 2.79 and a debt-to-equity ratio of 0.44. The firm has a 50 day simple moving average of $78.85 and a 200-day simple moving average of $72.74. The company has a market capitalization of $5.41 billion, a P/E ratio of 37.41, a PEG ratio of 2.27 and a beta of 0.49. Merit Medical Systems has a twelve month low of $59.74 and a twelve month high of $94.75.

Merit Medical Systems (NASDAQ:MMSI) last posted its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.23. Merit Medical Systems had a net margin of 9.22% and a return on equity of 13.75%. The firm had revenue of $418.84 million for the quarter, compared to analysts’ expectations of $405.25 million. During the same period in the prior year, the company posted $1.01 earnings per share. The firm’s quarterly revenue was up 9.5% on a year-over-year basis. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. On average, equities research analysts predict that Merit Medical Systems will post 3.84 earnings per share for the current fiscal year.

Institutional Trading of Merit Medical Systems

Hedge funds have recently made changes to their positions in the stock. Kilter Group LLC bought a new position in Merit Medical Systems during the 2nd quarter worth $25,000. Los Angeles Capital Management LLC acquired a new stake in Merit Medical Systems in the fourth quarter worth $25,000. Torren Management LLC bought a new stake in Merit Medical Systems in the fourth quarter valued at $38,000. Covestor Ltd boosted its holdings in shares of Merit Medical Systems by 252.6% during the fourth quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock valued at $41,000 after acquiring an additional 336 shares during the period. Finally, Danske Bank A S acquired a new position in shares of Merit Medical Systems during the third quarter valued at $42,000. Institutional investors own 99.66% of the company’s stock.

Merit Medical Systems News Roundup

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Zacks Research raised several earnings forecasts. The firm increased its FY2026 EPS estimate to $3.73 from $3.57, FY2027 to $4.01 from $3.82, and FY2028 to $4.32 from $4.12. It also lifted estimates for Q2 2027, Q3 2027, Q1 2028, and Q2 2028. The revisions suggest improved confidence in Merit Medical’s longer-term earnings growth.
• Positive Sentiment: Longer-term earnings expectations are moving higher. The revised FY2027 and FY2028 forecasts exceed the current-year consensus estimate of roughly $3.81–$3.84 per share, reinforcing the outlook for continued earnings expansion.
• Neutral Sentiment: Short-interest data appears unusable. The report lists short interest at zero shares and describes the change as “NaN,” with a zero days-to-cover ratio. This does not provide a meaningful signal about short-selling pressure or potential short covering.
• Negative Sentiment: One near-term estimate was reduced. Zacks lowered its Q4 2026 EPS forecast slightly to $0.98 from $0.99. While the change is minor, it offsets some of the broader positive revisions and indicates limited near-term earnings impact.
• Negative Sentiment: Valuation leaves less room for disappointment. Merit Medical’s shares recently traded near their 52-week high, with a P/E ratio above 37 and a PEG ratio above 2. Stronger earnings expectations are supportive, but the premium valuation could weigh on the stock if results or guidance fall short.

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.